Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2005 Jan;38(1):13-6.
doi: 10.1055/s-2005-837765.

Fluoxetine versus trimipramine in the treatment of depression in geriatric patients

P M Wehmeier  1 , M Kluge, A Maras, D Riemann, M Berger, R Kohnen, R W Dittmann, W F Gattaz
Affiliations
Clinical Trial

Fluoxetine versus trimipramine in the treatment of depression in geriatric patients

P M Wehmeier et al. Pharmacopsychiatry. 2005 Jan.

Abstract

Introduction: Fluoxetine, a selective serotonin reuptake inhibitor (SSRI), and trimipramine, a tricyclic antidepressant (TCA), were compared in terms of efficacy and tolerability in a six-week, parallel group, double-blind pilot study in 41 geriatric patients with major depression (61 - 85 years old).

Method: The Hamilton Rating Scale for Depression (HAMD-17), the Montgomery-Asberg Rating Scale (MADRS), the Adjective Mood Scale (Bf-S), the Clinical Global Impression (CGI), and the Patients Global Impression (PGI) were used to measure changes in depressive symptoms.

Results: Improvement with treatment was found on all scales. Efficacy and tolerability were similar in both groups. No statistically significant differences were found.

Conclusion: These findings suggest that fluoxetine and trimipramine are comparable in terms of efficacy and tolerability in the treatment of major depression in geriatric patients.

PubMed Disclaimer

Publication types

MeSH terms

LinkOut - more resources